Novo Holdings A/S 3
3 · Hemab Therapeutics Holdings, Inc. · Filed Apr 30, 2026
Insider Transaction Report
Form 3
Novo Holdings A/S
10% Owner
Holdings
Series Seed Preferred Stock
[F1]→ Common Stock (513,546 underlying)Series A Preferred Stock
[F1]→ Common Stock (1,581,052 underlying)Series B Preferred Stock
[F1]→ Common Stock (1,366,662 underlying)Series C Preferred Stock
[F1]→ Common Stock (719,290 underlying)
Footnotes (1)
- [F1]Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock will automatically convert into shares of Common Stock on a 22-for-1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date.
Signature
/s/ Barbara Fiorini, General Counsel, Finance & Operations of Novo Holdings A/S|2026-04-30